{"gene":"PAX5","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":1992,"finding":"PAX5 encodes the transcription factor BSAP; the intact paired domain is both necessary and sufficient for DNA binding of BSAP, and its DNA-binding sequence specificity differs from the related Pax-1 protein.","method":"Biochemical purification, cDNA cloning, DNA binding studies (EMSA)","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical purification and cDNA cloning with in vitro binding assays; foundational identification paper","pmids":["1516825"],"is_preprint":false},{"year":1992,"finding":"BSAP (PAX5) directly binds a high-affinity site in the CD19 gene promoter (occupying it in vivo in B cells but not in plasma or HeLa cells) and confers B-cell specificity in reporter assays, establishing CD19 as a direct PAX5 transcriptional target.","method":"In vitro protein-DNA binding, in vivo footprinting, transient transfection reporter assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (EMSA, in vivo footprinting, reporter assay); replicated in subsequent gene-targeting studies","pmids":["1375324"],"is_preprint":false},{"year":1994,"finding":"Targeted disruption of Pax5 in mice completely blocks B cell development at an early pro-B (pre-BI) cell stage, defining an essential role for Pax5 in early B lymphopoiesis, and also causes abnormal patterning of the posterior midbrain.","method":"Germline gene targeting (knockout mouse), histology, flow cytometry","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with defined cellular phenotype; widely replicated foundational study","pmids":["8001127"],"is_preprint":false},{"year":1994,"finding":"BSAP is required for LPS-induced B cell proliferation; antisense-mediated suppression of BSAP reduced proliferation, and overexpression stimulated proliferation, identifying BSAP as a rate-limiting regulator of B cell proliferation.","method":"Antisense oligonucleotide knockdown, overexpression by transfection, proliferation assays","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two methods (antisense KD and OE) in a single lab with defined proliferative phenotype","pmids":["7511679"],"is_preprint":false},{"year":1994,"finding":"BSAP binds the Iε promoter (forming complex 3) and is essential for LPS/IL-4-induced immunoglobulin germ-line epsilon transcription; a BSAP binding site from a heterologous promoter can substitute functionally for the epsilon-associated site.","method":"EMSA, transient transfection reporter assays (CAT)","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus functional reporter assay, single lab","pmids":["8144891"],"is_preprint":false},{"year":1995,"finding":"Three amino acids at positions 42, 44, and 47 of the paired domain N-terminal subdomain determine the difference in DNA-binding specificity between Pax-6 and BSAP (Pax-5); mutating these three Pax-6 residues to the corresponding BSAP residues completely switches binding specificity to BSAP.","method":"In vitro mutagenesis of fusion proteins, EMSA, transactivation assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct mutagenesis plus in vitro binding reconstitution establishing specific residues responsible for DNA-binding specificity","pmids":["7739566"],"is_preprint":false},{"year":1995,"finding":"BSAP represses the immunoglobulin heavy chain 3' alpha enhancer by blocking binding of NF-αP (an Ets family member) to the adjacent αP element; triple-helix-forming oligonucleotide blocking of BSAP binding in vivo derepressed the αP footprint and increased endogenous IgH transcription.","method":"In vitro binding, in vivo footprinting, triple-helix oligonucleotide transfection, reporter assay","journal":"Proceedings of the National Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo footprinting plus functional reporter assay plus oligonucleotide blocking, single lab","pmids":["7777508"],"is_preprint":false},{"year":1996,"finding":"The C-terminal serine/threonine/proline-rich region of BSAP contains a 55-amino-acid transactivation domain that is active from promoter and enhancer positions; this domain is negatively regulated by adjacent extreme C-terminal sequences; both elements function as an independent module conserved in Pax-2 and Pax-8.","method":"In vitro mutagenesis, transient transfection reporter assays, GAL4 fusion assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with functional reporter assay defining specific domain boundaries; cross-validated in multiple Pax family members","pmids":["8617244"],"is_preprint":false},{"year":1996,"finding":"Pax-5 (BSAP) functions as a cell-type-specific docking protein that recruits Ets proto-oncogene family proteins (Ets-1, Net, Elk-1 but not SAP1a) to form functional ternary complexes on the mb-1 promoter; complex assembly requires only the Pax-5 paired box and ETS DNA-binding domains; a single valine in the ETS domain of SAP1a versus aspartic acid in other Ets proteins determines selectivity.","method":"EMSA (ternary complex formation), mutagenesis, transient transfection reporter assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of ternary complex plus mutagenesis identifying specific residues; functionally validated in pre-B cell reporter assays","pmids":["8804314"],"is_preprint":false},{"year":1996,"finding":"BSAP directly activates the human epsilon germline promoter through binding sites identified by EMSA, contributing to both IL-4-dependent induction and CD40-mediated up-regulation of epsilon germline transcription in human B cells.","method":"EMSA, luciferase reporter assays with site-directed mutation of BSAP binding site","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus functional reporter assay with binding site mutations, single lab","pmids":["9190940"],"is_preprint":false},{"year":1997,"finding":"Pax5 is required for VH-to-DHJH rearrangement at the IgH locus in adult pro-B cells (~50-fold reduction) while DH-to-JH rearrangements occur at normal frequency; fetal and adult B lymphopoiesis have differential dependency on Pax5.","method":"Pax5 knockout mouse analysis, PCR-based rearrangement assays, transplantation experiments","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with quantitative molecular readout; multiple experimental conditions","pmids":["9042861"],"is_preprint":false},{"year":1997,"finding":"Overexpression of BSAP in a late B cell line suppressed Ig synthesis and reduced Blimp-1 expression, inhibiting differentiation to plasma cell phenotype; BSAP overexpression suppressed spontaneous appearance of high-Ig-secreting cells.","method":"Stable transfection, overexpression of BSAP expression plasmid, flow cytometry, Ig secretion assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — OE experiment with multiple phenotypic readouts (Blimp-1, syndecan-1, Ig secretion), single lab","pmids":["9120274"],"is_preprint":false},{"year":1997,"finding":"Cooperation of Pax2 and Pax5 is essential for normal functioning of the organizing center at the midbrain-hindbrain junction: compound heterozygous Pax5/Pax2 mutant mice show severe midbrain-cerebellar defects, and biallelic loss of both factors deletes the entire posterior midbrain/cerebellum.","method":"Double-mutant mouse genetics (Pax5 knockout × Krd deletion of Pax2 locus), morphological analysis","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in compound mutant mice with defined morphological phenotype","pmids":["9159136"],"is_preprint":false},{"year":1998,"finding":"Pax5 directly activates Ig-alpha (mb-1), N-myc, and LEF-1 genes and represses PD-1 in pro-B cells, as shown using a hormone-inducible BSAP-estrogen receptor fusion in Pax5-deficient pre-BI cells; the paired domain alone (without transactivation domain) was sufficient to restore mb-1 and LEF-1 expression, suggesting PAX5 acts as a docking protein for other factors at those genes.","method":"Hormone-inducible BSAP-ER fusion in Pax5-/- pre-BI cells, loss- and gain-of-function experiments, gene expression analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible reconstitution in null cells with domain-deletion analysis; multiple target genes tested; direct regulation demonstrated","pmids":["9545244"],"is_preprint":false},{"year":1998,"finding":"BSAP activator motifs have ~20-fold higher binding affinity than repressor motifs; a concentration-dependent mechanism selectively targets BSAP activities such that at higher concentrations repressor functions are engaged, while at lower concentrations only activator functions are maintained.","method":"DNA binding affinity measurements, reporter assays with swapped activator/repressor motifs","journal":"Science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative binding and functional assays, single lab","pmids":["9506950"],"is_preprint":false},{"year":1998,"finding":"Pax5 arrests B lymphopoiesis at a stage that is unresponsive to pre-BCR signaling; pre-BCR is stably expressed on Pax5-/- pre-BI cells but fails to signal; BCL2 overexpression does not rescue the block, indicating Pax5 has a role beyond survival signaling at this stage.","method":"Transgenic rescue experiments (Igmu, Igmu-Igbeta, bcl2 transgenes in Pax5-/- mice), in vitro culture assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic rescue attempts in null mice with defined signaling readout; epistasis analysis","pmids":["9705955"],"is_preprint":false},{"year":1999,"finding":"The partial homeodomain of Pax5 directly binds TBP (the TATA-binding protein) and the underphosphorylated form of Rb in vivo (by co-immunoprecipitation) and in vitro; interaction with TBP links Pax5 to the basal transcription machinery via TFIID; Rb interaction is cell-cycle regulated.","method":"Co-immunoprecipitation, in vitro GST pulldown, mutagenesis mapping","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP plus in vitro pulldown with domain mapping, single lab","pmids":["10197586"],"is_preprint":false},{"year":1999,"finding":"AML1 (CBFα2) physically interacts with the paired DNA-binding domain of BSAP/PAX5, and the two proteins synergistically activate the B-cell-specific blk promoter by more than 50-fold in transient transfection assays.","method":"In vitro binding assay, co-immunoprecipitation, transient transfection reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro binding plus co-IP plus functional reporter, single lab","pmids":["10455134"],"is_preprint":false},{"year":2000,"finding":"Pax5 exerts transcriptional repression by recruiting Groucho-family corepressors: yeast two-hybrid identified Grg4 as a Pax5 partner; interaction involves the octapeptide motif and C-terminal domain of Pax5, and the Q and SP regions of Grg4; Grg4 efficiently represses Pax5 transcriptional activity in an octapeptide-dependent manner; this Pax/Groucho interaction is conserved in Drosophila.","method":"Yeast two-hybrid screen, co-immunoprecipitation, domain deletion analysis, transient transfection reporter assays, Drosophila functional assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — yeast two-hybrid discovery + in vivo co-IP + domain mapping + functional reporter + cross-species validation; multiple orthogonal methods","pmids":["10811620"],"is_preprint":false},{"year":2000,"finding":"BSAP/Pax5 directly interacts with PU.1 through their respective DNA-binding domains; BSAP represses PU.1 transactivation through the BSAP inhibitory domain (residues 358–385) targeting PU.1 transactivation residues 7–30; this repression can be reversed by the coactivator p300.","method":"Co-immunoprecipitation, EMSA, transient transfection reporter assays with domain deletion mutants","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional domain mapping in reporter assays, single lab","pmids":["10688639"],"is_preprint":false},{"year":2000,"finding":"Nuclear translocation of Ref-1 (APE1) in response to oxidative stress (H2O2) in B lymphocytes transiently increases its nuclear levels and enhances BSAP/Pax5 DNA-binding activity; Ref-1 co-transfection increases Pax5 activation of the CD19 promoter 5–8-fold.","method":"Western blot, in situ immunocytochemistry, EMSA, co-transfection reporter assay","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cellular fractionation plus EMSA plus co-transfection, single lab with multiple methods","pmids":["10666449"],"is_preprint":false},{"year":2001,"finding":"Conditional inactivation of Pax5 in mature B cells (via CD19-cre or Mx-cre) causes loss of B cell identity: downregulation of B cell-specific genes and surface antigens, and upregulation of non-B lymphoid genes, demonstrating Pax5 is continuously required to maintain B cell identity throughout B lymphopoiesis.","method":"Conditional knockout mouse (Cre-lox), gene expression analysis, flow cytometry","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic loss-of-function with comprehensive phenotypic characterization; replicated in multiple cre drivers","pmids":["11420047"],"is_preprint":false},{"year":2002,"finding":"Pax5 directly represses transcription of Notch1, thereby blocking T cell development; pan-hematopoietic Pax5 expression strongly promoted B cell development at the expense of T lymphopoiesis but did not block myeloid development.","method":"Ikaros-locus knockin of Pax5 minigene, conditional/constitutive activation, flow cytometry, gene expression analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain-of-function knockin model with defined mechanistic readout (Notch1 repression); multiple experimental conditions","pmids":["12479824"],"is_preprint":false},{"year":2002,"finding":"Pax5 interacts with Daxx via the partial homeodomain of Pax5 and C-terminal fragment of Daxx; this interaction can result in either transcriptional corepression or coactivation in B cells; coactivation involves recruitment of CBP (co-precipitated in complexes containing Pax5, Daxx, and CBP).","method":"Yeast two-hybrid, transient transfection reporter assays, co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid + co-IP + functional reporter, single lab","pmids":["11799127"],"is_preprint":false},{"year":2002,"finding":"Early B cell factor (EBF), E2A, and Pax-5 cooperate to activate the mb-1 promoter: in vivo footprinting showed occupancy of EBF, E-box, and Pax-5 binding sites; EBF and E2A synergistically activated the promoter in non-B cells, and Pax-5 (with Ets partners) is required at all mb-1-expressing stages.","method":"In vivo footprinting, transient transfection reporter assays, DNA microarray expression analysis","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo footprinting plus functional reporter assays plus expression profiling, single lab","pmids":["12446773"],"is_preprint":false},{"year":2003,"finding":"CD40 stimulation induces nuclear translocation of APE/Ref-1, which then modulates DNA-binding activity of Pax5a/BSAP and EBF in activated B cells; repression of APE/Ref-1 blocks CD40-mediated Pax5a activation; Pax5a physically interacts with EBF and enhances EBF DNA-binding activity.","method":"Co-immunoprecipitation, EMSA, nuclear fractionation, transient transfection reporter assay, siRNA knockdown of Ref-1","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus EMSA plus functional reporter plus knockdown, single lab","pmids":["14594818"],"is_preprint":false},{"year":2003,"finding":"Mutations in the β-hairpin/β-turn of the Pax-5 paired domain DNA-binding domain reduce DNA sequence recognition and mb-1 transcription activation; specific amino acids contacting Ets-1 in the crystal structure are required for Ets recruitment and mb-1 transcription; mutation Q22A selectively abolishes Fli-1 recruitment without affecting GABPα recruitment.","method":"Crystal structure-guided mutagenesis, cell-based transcription assay, in vitro EMSA","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structure-guided mutagenesis with cell-based functional assay; defines specific contact residues for partner selectivity","pmids":["14500810"],"is_preprint":false},{"year":2004,"finding":"Pax5 induces large-scale contraction of the IgH locus and distal VH-DJH rearrangements; reconstitution of Pax5 in Pax5-/- pro-B cells is sufficient to trigger locus contraction and distal VH-DJH recombination; ectopic Pax5 in thymocytes induces only proximal VH-DJH rearrangements (no locus contraction), indicating a pro-B-specific cofactor is required.","method":"Retroviral Pax5 reconstitution in Pax5-/- pro-B cells, 3D FISH locus contraction assay, VDJ recombination PCR, Ikaros-Pax5 knockin thymocyte analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic reconstitution plus 3D FISH plus recombination PCR; multiple complementary approaches in same study","pmids":["15004008"],"is_preprint":false},{"year":2004,"finding":"Pax-5 directly activates kappa sterile transcription and is required for Ig kappa chain gene rearrangement; the transactivation domain of Pax-5 is required for this function; in Pax5-deficient pre-BI cells the Jκ locus localizes to the nuclear periphery (repressive compartment), and Pax5 expression repositions it and enables rearrangement.","method":"Hormone-inducible Pax5 reconstitution in Pax5-/- pre-BI cells, RT-PCR, FISH nuclear localization assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible reconstitution in null cells + FISH nuclear localization + domain analysis, multiple orthogonal methods","pmids":["15067064"],"is_preprint":false},{"year":2006,"finding":"Pax5 directly binds multiple sites in VH gene coding regions in vitro and occupies VH genes in early B lineage cells in vivo; Pax5 physically interacts with the RAG1-RAG2 complex to enhance RAG-mediated VH recombination signal sequence cleavage and recombination of a VH gene substrate.","method":"ChIP, EMSA, co-immunoprecipitation (Pax5–RAG1/RAG2), in vitro V(D)J recombination assay","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP plus in vitro RAG interaction plus in vitro cleavage/recombination assay; multiple orthogonal methods","pmids":["16680144"],"is_preprint":false},{"year":2006,"finding":"Deletion of Pax5 in Pax5-deficient DT40 B cells leads to loss of BCR signaling, upregulation of Blimp-1 and XBP-1, downregulation of Bcl-6, and elevated IgM secretion, demonstrating that Pax5 represses plasma cell differentiation; restoration of Pax5 expression normalizes this transcriptional program.","method":"Gene targeting (Pax5 deletion in DT40), rescue by Pax5 re-expression, RT-PCR, IgM secretion assay, BCR signaling assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO plus rescue reconstitution with multiple molecular readouts in same study","pmids":["16546097"],"is_preprint":false},{"year":2007,"finding":"Pax5 in B lymphomas maintains expression of BCR signaling components (including CD79a/Igα) while repressing ITAM antagonists CD22 and PIR-B; Pax5-dependent BCR/ITAM signaling promotes neoplastic growth, as shown by dominant-negative Pax5 and Pax5 knockdown reducing lymphoma cell expansion.","method":"Tamoxifen-inducible Pax5-ER fusion protein, dominant-negative Pax5, shRNA knockdown, expression profiling, Syk inhibitor pharmacology","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible gain-of-function plus DN and KD loss-of-function with expression profiling and defined signaling pathway; multiple orthogonal approaches","pmids":["17717600"],"is_preprint":false},{"year":2007,"finding":"BSAP/Pax5 directly binds Wp (Epstein-Barr virus transforming promoter) on the viral genome in transformed B cells (ChIP); mutation of BSAP binding sites in recombinant EBV completely abolishes Wp activity and outgrowth of transformed cells in B cells, while EBV entry into epithelial cells is unaffected.","method":"Chromatin immunoprecipitation (ChIP) on viral genome, recombinant EBV with Wp BSAP binding site mutations","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP plus recombinant virus mutagenesis with biological readout; rigorous mechanistic test","pmids":["17626071"],"is_preprint":false},{"year":2007,"finding":"BSAP/PAX5 directly represses PRDM1 (Blimp1) transcription by binding to its promoter in vivo, forming an autoregulatory negative-feedback loop that maintains B cell identity and restrains plasma cell differentiation.","method":"EMSA, ChIP, ectopic BSAP expression with PRDM1 promoter reporter (including BSAP binding site mutant)","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — EMSA plus ChIP plus functional reporter with site mutation; multiple orthogonal methods","pmids":["17682124"],"is_preprint":false},{"year":2000,"finding":"The nuclear localization of BSAP/Pax5 is mediated by a defined NLS sequence (NKRKRDE, amino acids 195–201) in the central domain that binds importin alpha1 (Rch1); this NLS was confirmed by yeast two-hybrid, GST pulldown, and by conferring nuclear localization on GFP fusion proteins.","method":"Yeast two-hybrid, GST pulldown, GFP-fusion nuclear localization assay, mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — yeast two-hybrid + in vitro pulldown + live cell localization assay with mutagenesis; multiple orthogonal methods","pmids":["10748034"],"is_preprint":false},{"year":2011,"finding":"PAX5 fusion leukemia proteins act as dominant-negatives by multimerizing their DNA-binding domains (via partner-derived oligomerization sequences), resulting in extremely stable chromatin binding (measured by FRAP) and competition with wild-type PAX5 for target sites; tetramerization (not corepressor-binding motifs) is necessary and sufficient for dominant-negative activity.","method":"FRAP in living cells, in vitro DNA binding assays, domain deletion/mutagenesis, artificial dimerization/trimerization/tetramerization domain fusions","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — FRAP plus in vitro binding reconstitution plus systematic domain dissection with artificial oligomerization domains; single lab but multiple orthogonal methods","pmids":["21765475"],"is_preprint":false},{"year":2011,"finding":"PAX5-PML fusion protein acts as dual dominant-negative for both PAX5 and PML: it inhibits PAX5 transcriptional activity and suppresses PAX5 target gene expression (despite retaining PAX5 DBD, it binds promoters through association with endogenous PAX5 rather than direct DNA binding); it also disrupts PML nuclear bodies, inhibits PML sumoylation, and confers apoptosis resistance reversible by arsenic trioxide.","method":"Luciferase reporter assay, ChIP, co-immunoprecipitation, sumoylation assay, PML-NB immunofluorescence, apoptosis assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus ChIP plus functional reporter plus NB disruption assay, single lab","pmids":["21217775"],"is_preprint":false},{"year":2013,"finding":"SOX11 directly binds the PAX5 locus (identified by ChIP-microarray) and regulates PAX5 expression; SOX11 knockdown downregulates PAX5, induces BLIMP1 expression, and promotes plasmacytic differentiation in MCL cells.","method":"ChIP-microarray, siRNA knockdown, gene expression profiling, flow cytometry","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus KD with expression profiling, single lab; PAX5 is here an output rather than the actor","pmids":["23321250"],"is_preprint":false},{"year":2015,"finding":"EBV noncoding RNA EBER2 directly interacts with PAX5 protein and is required for PAX5 localization to the terminal repeats of the latent EBV genome; this recruitment is mediated by base-pairing between EBER2 and nascent transcripts from the terminal repeat locus; EBER2 knockdown phenocopies PAX5 depletion in upregulating LMP2A/B and LMP1.","method":"CHART (Capture Hybridization Analysis of RNA Targets), co-immunoprecipitation (EBER2–PAX5), EBER2 knockdown, reporter/ChIP assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — CHART genomic localization + co-IP of RNA-protein complex + knockdown phenocopy + base-pairing mechanism; multiple orthogonal methods","pmids":["25662012"],"is_preprint":false},{"year":2018,"finding":"In human primordial germ cell (hPGC) development, PAX5 forms a core transcriptional network with OCT4 and PRDM1; PAX5 switches OCT4 from its pluripotency partner SOX2 to drive germline specification; PAX5 acts upstream of OCT4 and PRDM1 by epistasis; PAX5 loss-of-function impairs hPGC development.","method":"ChIP-seq (OCT4 occupancy in hPGCs vs hESCs), gain- and loss-of-function (genome editing), epistasis analysis, in vitro differentiation and xenograft engraftment","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq plus genome editing gain/loss-of-function plus epistasis; multiple orthogonal methods","pmids":["29713018"],"is_preprint":false},{"year":2019,"finding":"The PAX5 p.Pro80Arg mutation impairs B lymphoid development and promotes B-ALL with biallelic PAX5 alteration in vivo, demonstrating a gain-of-leukemogenic function for this specific missense mutation.","method":"In vivo mouse model with PAX5 P80R knockin, B cell developmental assays, B-ALL disease induction","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockin mouse model with defined cellular phenotype and disease induction","pmids":["30643249"],"is_preprint":false},{"year":2021,"finding":"Pax5 restrains PTEN protein expression at the posttranscriptional level (likely through Pten-targeting microRNAs), thereby promoting PI3K-AKT signaling in mature B cells; Pax5-deficient follicular B cells fail to proliferate upon BCR or TLR stimulation due to increased PTEN and impaired PI3K signaling; additional PTEN loss in Pten,Pax5 double-mutant mice rescues follicular and marginal zone B cell numbers but not germinal center formation.","method":"Conditional knockout mouse (Pax5 deletion in peripheral B cells), Pten/Pax5 double-mutant mice, Western blot (PTEN protein), PI3K-AKT signaling assays, B cell stimulation/proliferation assays","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO plus double-mutant epistasis plus molecular signaling readout; multiple orthogonal methods in same study","pmids":["34301800"],"is_preprint":false},{"year":2021,"finding":"EBF1 and PAX5 bind opposing regulatory elements in the Myc locus and regulate Myc in an opposing manner: EBF1 activates Myc expression (critical for pro-B cell expansion) while ectopic PAX5 in EBF1-deficient cells inhibits cell cycle and reduces Myc expression; Pax5 inactivation reduces EBF1 requirements for pro-B cell expansion.","method":"Chromosome conformation analysis, ATAC-seq, ChIP-seq, CRISPR-Cas9 targeting of EBF1-binding sites, reporter assay, conditional KO mouse","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq + ATAC + CCA + CRISPR perturbation + genetic epistasis; multiple orthogonal methods","pmids":["33619557"],"is_preprint":false},{"year":2022,"finding":"PAX5 acts as a key activator of CD58 expression at the CD58 locus through an epigenetically defined enhancer; the PAX5 P80R mutation disrupts this enhancer, reducing CD58 expression and conferring blinatumomab resistance in B-ALL.","method":"Genome-wide CRISPR screen, transcription factor screen (1639 TFs), genome editing (P80R mutation), ChIP/ATAC-seq at CD58 locus","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide CRISPR screen + targeted genome editing + ChIP/epigenome at specific locus; multiple orthogonal methods","pmids":["36516256"],"is_preprint":false},{"year":2022,"finding":"The PAX5-JAK2 fusion protein functions as a nuclear driver of B-ALL: its DNA-binding function (via PAX5 DBD) and kinase activity (via JAK2 domain) are both required for leukemogenesis; PAX5-JAK2 phosphorylates STAT5 in the nucleus, sustaining high levels of active nuclear pSTAT5 and STAT5 target gene expression.","method":"Endogenous locus Pax5-Jak2 knockin mouse, domain-specific mutagenesis (kinase-dead, DNA-binding mutants), phospho-STAT5 Western blot/ChIP, RNA-seq","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — endogenous knockin model plus domain mutagenesis plus nuclear signaling readout; multiple orthogonal methods","pmids":["35156727"],"is_preprint":false},{"year":2022,"finding":"Biallelic loss-of-function mutations in PAX5 cause hypogammaglobulinemia (due to early B cell developmental block), defective immune responses, aberrant cerebellar foliation, hypoplasia of the substantia nigra and ventral tegmental area (loss of GABAergic neurons), and ASD-like behavioral deficits; lineage tracing identifies Pax5 as a crucial regulator of cerebellar morphogenesis and midbrain GABAergic neurogenesis.","method":"Patient-specific Pax5 knockin mouse, flow cytometry, behavioral testing, histology/lineage tracing, immune response assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — patient-specific mouse model with lineage tracing plus multiple orthogonal phenotypic readouts; identifies new roles in brain development","pmids":["35947077"],"is_preprint":false},{"year":2024,"finding":"Acute in vivo degradation of Pax5 protein in pro-B, small pre-B, and immature B cells revealed that Pax5 functions predominantly as a transcriptional activator by inducing open chromatin at target genes; Pax5 directly activates Rag1, Rag2, Dntt, Irf4, and Irf8 (contributing to V(D)J recombination); Pax5, like Ebf1, represses the cohesin-release factor Wapl to mediate prolonged loop extrusion across the Igh locus; Pax5 co-activates Igll1 and Vpreb1 surrogate light-chain genes in pro-B cells.","method":"Acute protein degradation (dTAG system) in mice, ATAC-seq, ChIP-seq, RNA-seq across multiple B cell developmental stages","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — acute in vivo protein degradation (avoiding compensation) plus genome-wide chromatin and expression analysis across multiple stages; highly rigorous multi-method study","pmids":["39179932"],"is_preprint":false},{"year":2009,"finding":"PAX5 directly regulates c-Met transcription in small-cell lung cancer (SCLC) cells; PAX5 binds the c-Met promoter (shown by luciferase reporter and ChIP); phospho-c-Met and PAX5 co-localize in the nucleus and physically interact; PAX5 knockdown decreases SCLC cell viability, especially with c-Met or topoisomerase inhibitors.","method":"Luciferase reporter assay, ChIP, co-immunoprecipitation, immunofluorescence co-localization, siRNA knockdown + drug treatment","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional reporter plus co-IP, single lab; context is non-B cell (SCLC)","pmids":["19139719"],"is_preprint":false},{"year":2020,"finding":"Repression of Pax5 by Blimp1 is NOT required for plasma cell development; mice expressing a Pax5 minigene ectopically in plasma cells (IghPax5/+) still efficiently develop plasma cells and secrete antibodies, though IgG secretion is modestly decreased and long-lived plasma cells are reduced in older mice.","method":"IghPax5/+ knockin mouse (Pax5 minigene expressed from IgH locus), plasma cell development analysis, antibody secretion assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain-of-function knockin with multiple functional readouts; directly tests and refutes a prevailing model","pmids":["32780801"],"is_preprint":false}],"current_model":"PAX5 (BSAP) is a paired-domain transcription factor that functions as the master regulator of B cell identity throughout lymphopoiesis: it binds target gene promoters/enhancers via its N-terminal paired domain (with DNA-binding specificity determined by three key residues), recruits Ets family proteins as ternary complex partners, activates B-lineage genes (CD19, mb-1/Igα, N-myc, LEF-1, Rag1/2, Dntt, Igll1/Vpreb1) and represses non-B-lineage and plasma cell genes (Notch1, PD-1, PRDM1/Blimp1) through distinct mechanisms including corepressor recruitment (Groucho/Grg4 via its octapeptide motif), physical antagonism of PU.1, and interaction with TBP/TFIID and Rb; it induces IgH locus contraction to enable distal VH-DJH recombination by repressing the cohesin-release factor Wapl, directly interacts with the RAG1-RAG2 complex to enhance V(D)J cleavage, and posttranscriptionally down-regulates PTEN to promote PI3K-AKT signaling in mature B cells; its nuclear import requires a defined NLS (aa 195–201) that binds importin α1; in leukemia, PAX5 fusion proteins act as dominant-negatives via DBD multimerization and the PAX5-JAK2 fusion phosphorylates nuclear STAT5, while the PAX5 P80R mutation disrupts a CD58 enhancer to confer immunotherapy resistance."},"narrative":{"mechanistic_narrative":"PAX5 (BSAP) is a paired-domain transcription factor that serves as the master regulator of B-cell identity throughout lymphopoiesis, where it is both required to commit progenitors to the B lineage and continuously required to maintain that identity in mature B cells [PMID:8001127, PMID:11420047]. Its N-terminal paired domain is necessary and sufficient for sequence-specific DNA binding, with three residues at positions 42, 44 and 47 determining its target specificity relative to other Pax proteins [PMID:1516825, PMID:7739566]. PAX5 functions both as a direct activator of B-lineage genes — CD19, mb-1/Igα, N-myc, LEF-1, and the surrogate light-chain genes Igll1/Vpreb1 — and as a repressor of lineage-inappropriate and plasma-cell programs, repressing Notch1 to block T-cell development and repressing PRDM1/Blimp1 in an autoregulatory loop that restrains plasma-cell differentiation [PMID:1375324, PMID:9545244, PMID:12479824, PMID:17682124, PMID:39179932]. Acute in vivo degradation establishes that PAX5 acts predominantly as a transcriptional activator that induces open chromatin at target genes, directly activating Rag1, Rag2, Dntt, Irf4 and Irf8 [PMID:39179932]. Mechanistically, PAX5 operates as a cell-type-specific docking platform: it recruits Ets-family proteins (Ets-1, Net, Elk-1, Fli-1) into ternary complexes on the mb-1 promoter, cooperates with EBF, E2A and AML1, recruits Groucho/Grg4 corepressors through its octapeptide motif, and contacts the basal machinery via TBP and Rb [PMID:8804314, PMID:10197586, PMID:10455134, PMID:10811620, PMID:12446773, PMID:14500810]. It orchestrates antigen-receptor assembly by inducing large-scale IgH locus contraction to enable distal VH-DJH recombination — repressing the cohesin-release factor Wapl to sustain loop extrusion — and by directly interacting with the RAG1-RAG2 complex to enhance V(D)J cleavage [PMID:15004008, PMID:16680144, PMID:39179932]. In mature B cells PAX5 sustains BCR signaling and posttranscriptionally restrains PTEN to promote PI3K-AKT signaling [PMID:17717600, PMID:34301800]. PAX5 also functions outside the B lineage, forming a core network with OCT4 and PRDM1 to drive human primordial germ-cell specification [PMID:29713018]. In leukemia, PAX5 fusion proteins act as dominant-negatives via DNA-binding-domain multimerization, the PAX5-JAK2 fusion drives B-ALL by phosphorylating nuclear STAT5, and the PAX5 P80R mutation disrupts a CD58 enhancer to confer blinatumomab resistance [PMID:21765475, PMID:36516256, PMID:35156727]. Biallelic loss-of-function PAX5 mutations cause human hypogammaglobulinemia with cerebellar and midbrain neurodevelopmental defects [PMID:35947077].","teleology":[{"year":1992,"claim":"Establishing the molecular identity of BSAP answered whether a single factor underlies B-cell-specific gene regulation, defining PAX5 as a paired-domain transcription factor with intrinsic DNA-binding specificity and a bona fide B-lineage target.","evidence":"Biochemical purification, cDNA cloning and EMSA; in vivo footprinting and reporter assays on the CD19 promoter","pmids":["1516825","1375324"],"confidence":"High","gaps":["Did not define the full target gene network","No structural basis for specificity yet"]},{"year":1994,"claim":"Germline knockout answered where PAX5 acts in development, showing it is essential for progression past the early pro-B stage and also patterns the posterior midbrain, revealing a non-redundant role at a developmental checkpoint.","evidence":"Pax5 knockout mouse with histology and flow cytometry; antisense knockdown and overexpression proliferation assays","pmids":["8001127","7511679"],"confidence":"High","gaps":["Did not identify the direct target genes mediating the block","Mechanism of midbrain patterning unresolved"]},{"year":1995,"claim":"Domain dissection answered how DNA-binding specificity is encoded, identifying three paired-domain residues that switch specificity and showing PAX5 can repress by competing for overlapping Ets sites.","evidence":"In vitro mutagenesis of paired-domain fusion proteins, EMSA, transactivation assays; in vivo footprinting with triple-helix blocking at the IgH 3' enhancer","pmids":["7739566","7777508"],"confidence":"High","gaps":["Repression of the 3' enhancer is Medium-confidence single-lab","No structural model of the paired domain-DNA complex"]},{"year":1996,"claim":"Identifying the transactivation domain and the Ets-docking function answered how PAX5 actively regulates transcription, defining it as a modular activator and a recruitment platform for partner factors.","evidence":"GAL4-fusion and reporter mutagenesis mapping the C-terminal transactivation domain; EMSA ternary-complex reconstitution with Ets proteins and selectivity mutagenesis on the mb-1 promoter","pmids":["8617244","8804314"],"confidence":"High","gaps":["Endogenous coactivators recruited by the transactivation domain not defined","Ternary complexes shown in vitro/reporter, not at native chromatin"]},{"year":1998,"claim":"Inducible reconstitution in null cells answered which genes PAX5 directly controls, distinguishing genes activated via docking from those requiring the transactivation domain, and revealing a concentration-dependent activator/repressor switch.","evidence":"Hormone-inducible BSAP-ER in Pax5-/- pre-BI cells with domain deletions; quantitative binding-affinity and motif-swap reporter assays; transgenic rescue of the pre-BCR signaling block","pmids":["9545244","9506950","9705955"],"confidence":"High","gaps":["Affinity-threshold model is Medium-confidence single-lab","Identity of docked factors at mb-1/LEF-1 not established"]},{"year":2000,"claim":"Partner and corepressor mapping answered how PAX5 mechanistically represses and how it enters the nucleus, identifying Groucho/Grg4 recruitment via the octapeptide, antagonism of PU.1, and a defined importin-α1-binding NLS.","evidence":"Yeast two-hybrid, co-IP and domain mapping for Grg4 and PU.1; GST pulldown and GFP-fusion localization assays for the NLS (aa 195-201)","pmids":["10811620","10688639","10748034"],"confidence":"High","gaps":["PU.1 antagonism is Medium-confidence single-lab","Full corepressor complex composition not defined"]},{"year":2001,"claim":"Conditional inactivation answered whether PAX5 is needed only for commitment or continuously, showing mature B cells lose B identity and dedifferentiate without it, establishing PAX5 as a maintenance factor.","evidence":"Cre-lox conditional knockout with expression profiling and flow cytometry","pmids":["11420047"],"confidence":"High","gaps":["Did not resolve which targets are most critical for identity maintenance"]},{"year":2002,"claim":"Gain-of-function and partner studies answered how PAX5 enforces lineage choice, showing it represses Notch1 to suppress T-cell fate and engages Daxx/CBP for context-dependent regulation.","evidence":"Ikaros-locus Pax5 knockin with flow cytometry and expression analysis; yeast two-hybrid and co-IP for Daxx","pmids":["12479824","11799127"],"confidence":"High","gaps":["Daxx coactivation/corepression switch is Medium-confidence single-lab","Notch1 repression mechanism at the locus not detailed"]},{"year":2004,"claim":"Locus-architecture studies answered how PAX5 enables distal antigen-receptor recombination, showing it induces IgH locus contraction and repositions the Igκ locus out of repressive nuclear compartments.","evidence":"Retroviral reconstitution in Pax5-/- pro-B cells with 3D FISH and VDJ recombination PCR; FISH nuclear localization of the Jκ locus","pmids":["15004008","15067064"],"confidence":"High","gaps":["The pro-B-specific cofactor required for contraction was not identified","Molecular link between PAX5 and the contraction machinery unresolved at the time"]},{"year":2006,"claim":"Biochemical and genetic studies answered how PAX5 acts directly within V(D)J recombination and how it restrains plasma-cell fate, showing it binds VH coding regions and the RAG1-RAG2 complex to enhance cleavage and represses the Blimp-1/XBP-1 program.","evidence":"ChIP, EMSA, RAG1/2 co-IP and in vitro V(D)J recombination assay; Pax5 deletion and rescue in DT40 cells","pmids":["16680144","16546097"],"confidence":"High","gaps":["Stoichiometry of the PAX5-RAG complex not defined","How PAX5 mechanistically enhances cleavage at the active site unresolved"]},{"year":2007,"claim":"Studies in lymphoma and EBV answered how PAX5 sustains malignant and viral B-cell programs, showing it maintains BCR/ITAM signaling for neoplastic growth, autoregulates PRDM1, and drives the EBV Wp transforming promoter.","evidence":"Inducible PAX5-ER, dominant-negative and shRNA approaches with expression profiling; ChIP and recombinant-EBV mutagenesis; EMSA/ChIP/reporter on PRDM1","pmids":["17717600","17682124","17626071"],"confidence":"High","gaps":["Direct vs indirect maintenance of individual BCR components not fully parsed"]},{"year":2018,"claim":"Work in primordial germ cells answered whether PAX5 functions beyond the B lineage, showing it forms a core network with OCT4 and PRDM1 and switches OCT4 from a pluripotency to a germline program.","evidence":"ChIP-seq of OCT4 occupancy, genome-editing gain/loss-of-function, epistasis and xenograft engraftment in human PGCs","pmids":["29713018"],"confidence":"High","gaps":["How PAX5 redirects OCT4 partner choice mechanistically not defined"]},{"year":2011,"claim":"Mechanistic dissection of leukemic fusions answered how PAX5 rearrangements drive disease, showing fusion-driven oligomerization of the DNA-binding domain produces dominant-negative, chromatin-locked competitors of wild-type PAX5.","evidence":"FRAP in living cells, in vitro DNA binding, and artificial oligomerization-domain fusions; PAX5-PML co-IP, ChIP and PML-NB disruption assays","pmids":["21765475","21217775"],"confidence":"High","gaps":["PAX5-PML dual mechanism is Medium-confidence single-lab","Target genes most relevant to transformation not enumerated"]},{"year":2021,"claim":"Conditional and double-mutant studies answered how PAX5 supports mature-B-cell signaling, showing it posttranscriptionally restrains PTEN to enable PI3K-AKT signaling and opposes EBF1 at the Myc locus.","evidence":"Pax5 and Pten/Pax5 conditional and double-mutant mice with PI3K-AKT signaling and proliferation assays; ChIP-seq, ATAC-seq, CCA and CRISPR editing at the Myc locus","pmids":["34301800","33619557"],"confidence":"High","gaps":["The specific PTEN-targeting microRNAs were not definitively identified","Mechanism of opposing EBF1/PAX5 occupancy at Myc not fully resolved"]},{"year":2022,"claim":"In vivo models of specific mutations answered how PAX5 alterations cause B-ALL and treatment resistance, showing the JAK2 fusion phosphorylates nuclear STAT5 and the P80R mutation disrupts a CD58 enhancer to confer blinatumomab resistance.","evidence":"Endogenous-locus Pax5-Jak2 knockin with domain mutagenesis and pSTAT5 readouts; genome-wide CRISPR and TF screens with P80R genome editing and ChIP/ATAC at CD58; P80R knockin disease model; refutation of Blimp1-mediated Pax5 repression requirement","pmids":["35156727","36516256","30643249","32780801"],"confidence":"High","gaps":["Full set of nuclear pSTAT5 targets driving leukemogenesis not catalogued","How P80R remodels enhancer chromatin mechanistically not fully resolved"]},{"year":2024,"claim":"Acute protein degradation answered the long-standing question of PAX5's predominant regulatory mode without compensation, showing it acts mainly as an activator that opens chromatin at direct targets including Rag1/2, Dntt, Irf4/8 and surrogate light-chain genes, and represses Wapl to sustain Igh loop extrusion.","evidence":"dTAG acute degradation in mice with stage-resolved ATAC-seq, ChIP-seq and RNA-seq","pmids":["39179932"],"confidence":"High","gaps":["Direct coactivators delivering chromatin opening not identified","Mechanism of Wapl repression at the molecular level not defined"]},{"year":null,"claim":"How PAX5 mechanistically couples to chromatin-remodeling and loop-extrusion machinery to open target genes and reposition antigen-receptor loci remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No defined PAX5-recruited remodeling complex","Direct link between PAX5 and cohesin/Wapl regulation undefined","Structural basis of PAX5-RAG and PAX5-Ets complexes on native chromatin lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,13,22,33,46]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,5,1,29]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[8,13,24]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[38]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[34,1]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[44,47]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,13,33,46]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,21,27,29]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,12,39,45]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[35,40,43,44]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[31,41,44]}],"complexes":[],"partners":["ETS1","EBF1","RUNX1","TBP","RB1","TLE4","SPI1","RAG1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q02548","full_name":"Paired box protein Pax-5","aliases":["B-cell-specific transcription factor","BSAP"],"length_aa":391,"mass_kda":42.1,"function":"Transcription factor that plays an essential role in commitment of lymphoid progenitors to the B-lymphocyte lineage (PubMed:10811620, PubMed:27181361). Fulfills a dual role by repressing B-lineage inappropriate genes and simultaneously activating B-lineage-specific genes (PubMed:10811620, PubMed:27181361). In turn, regulates cell adhesion and migration, induces V(H)-to-D(H)J(H) recombination, facilitates pre-B-cell receptor signaling and promotes development to the mature B-cell stage (PubMed:32612238). Repression of the cohesin-release factor WAPL causes global changes of the chromosomal architecture in pro-B cells to facilitate the generation of a diverse antibody repertoire (PubMed:32612238) (Microbial infection) Plays an essential role in the maintenance of Epstein-Barr virus genome copy number within the host cell by promoting EBNA1/oriP-dependent binding and transcription (PubMed:31941781). Also participates in the inhibition of lytic EBV reactivation by modulating viral BZLF1 activity (PubMed:23678172)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q02548/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PAX5","classification":"Not Classified","n_dependent_lines":47,"n_total_lines":1208,"dependency_fraction":0.03890728476821192},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PAX5","total_profiled":1310},"omim":[{"mim_id":"618893","title":"NUCLEOLAR PROTEIN 4-LIKE; NOL4L","url":"https://www.omim.org/entry/618893"},{"mim_id":"616205","title":"MICRO RNA 648; MIR648","url":"https://www.omim.org/entry/616205"},{"mim_id":"615545","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 3; ALL3","url":"https://www.omim.org/entry/615545"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"612724","title":"ALDOLASE B, FRUCTOSE-BISPHOSPHATE; ALDOB","url":"https://www.omim.org/entry/612724"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":37.0}],"url":"https://www.proteinatlas.org/search/PAX5"},"hgnc":{"alias_symbol":["BSAP","PAX-5"],"prev_symbol":[]},"alphafold":{"accession":"Q02548","domains":[{"cath_id":"1.10.10.10","chopping":"18-74","consensus_level":"high","plddt":96.136,"start":18,"end":74},{"cath_id":"1.10.10.10","chopping":"92-134","consensus_level":"high","plddt":93.8105,"start":92,"end":134}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02548","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q02548-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q02548-F1-predicted_aligned_error_v6.png","plddt_mean":63.22},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PAX5","jax_strain_url":"https://www.jax.org/strain/search?query=PAX5"},"sequence":{"accession":"Q02548","fasta_url":"https://rest.uniprot.org/uniprotkb/Q02548.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q02548/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02548"}},"corpus_meta":[{"pmid":"8001127","id":"PMC_8001127","title":"Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP.","date":"1994","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8001127","citation_count":667,"is_preprint":false},{"pmid":"17440452","id":"PMC_17440452","title":"Pax5: the guardian of B cell identity and function.","date":"2007","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17440452","citation_count":511,"is_preprint":false},{"pmid":"1516825","id":"PMC_1516825","title":"Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis.","date":"1992","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1516825","citation_count":484,"is_preprint":false},{"pmid":"30643249","id":"PMC_30643249","title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.","date":"2019","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30643249","citation_count":472,"is_preprint":false},{"pmid":"9042861","id":"PMC_9042861","title":"Essential functions of Pax5 (BSAP) in pro-B cell development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ recombination at the IgH locus.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9042861","citation_count":329,"is_preprint":false},{"pmid":"15004008","id":"PMC_15004008","title":"Pax5 induces V-to-DJ rearrangements and locus contraction of the immunoglobulin heavy-chain gene.","date":"2004","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15004008","citation_count":325,"is_preprint":false},{"pmid":"1375324","id":"PMC_1375324","title":"The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1375324","citation_count":297,"is_preprint":false},{"pmid":"7739566","id":"PMC_7739566","title":"DNA-binding and transactivation properties of Pax-6: three amino acids in the paired domain are responsible for the different sequence recognition of Pax-6 and BSAP (Pax-5).","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7739566","citation_count":252,"is_preprint":false},{"pmid":"9545244","id":"PMC_9545244","title":"Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9545244","citation_count":248,"is_preprint":false},{"pmid":"10811620","id":"PMC_10811620","title":"Transcriptional repression by Pax5 (BSAP) through interaction with corepressors of the Groucho family.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10811620","citation_count":212,"is_preprint":false},{"pmid":"8804314","id":"PMC_8804314","title":"Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter.","date":"1996","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8804314","citation_count":203,"is_preprint":false},{"pmid":"11420047","id":"PMC_11420047","title":"Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis.","date":"2001","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11420047","citation_count":196,"is_preprint":false},{"pmid":"21970955","id":"PMC_21970955","title":"Pax5: a master regulator of B cell development and leukemogenesis.","date":"2011","source":"Advances in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21970955","citation_count":191,"is_preprint":false},{"pmid":"12479824","id":"PMC_12479824","title":"Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12479824","citation_count":180,"is_preprint":false},{"pmid":"16546097","id":"PMC_16546097","title":"Loss of Pax5 promotes plasma cell differentiation.","date":"2006","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16546097","citation_count":171,"is_preprint":false},{"pmid":"9159136","id":"PMC_9159136","title":"Cooperation of Pax2 and Pax5 in midbrain and cerebellum development.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9159136","citation_count":144,"is_preprint":false},{"pmid":"8617244","id":"PMC_8617244","title":"C-terminal activating and inhibitory domains determine the transactivation potential of BSAP (Pax-5), Pax-2 and Pax-8.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8617244","citation_count":133,"is_preprint":false},{"pmid":"7511679","id":"PMC_7511679","title":"The B cell-specific transcription factor BSAP regulates B cell proliferation.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7511679","citation_count":132,"is_preprint":false},{"pmid":"25662012","id":"PMC_25662012","title":"EBV noncoding RNA binds nascent RNA to drive host PAX5 to viral DNA.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25662012","citation_count":130,"is_preprint":false},{"pmid":"7777574","id":"PMC_7777574","title":"Deregulated expression of PAX5 in medulloblastoma.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7777574","citation_count":119,"is_preprint":false},{"pmid":"23321250","id":"PMC_23321250","title":"SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23321250","citation_count":119,"is_preprint":false},{"pmid":"9694719","id":"PMC_9694719","title":"Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9694719","citation_count":115,"is_preprint":false},{"pmid":"11799127","id":"PMC_11799127","title":"The interaction of Pax5 (BSAP) with Daxx can result in transcriptional activation in B cells.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11799127","citation_count":97,"is_preprint":false},{"pmid":"8885870","id":"PMC_8885870","title":"An interleukin-2 signal relieves BSAP (Pax5)-mediated repression of the immunoglobulin J chain gene.","date":"1996","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8885870","citation_count":94,"is_preprint":false},{"pmid":"19139719","id":"PMC_19139719","title":"PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.","date":"2009","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19139719","citation_count":90,"is_preprint":false},{"pmid":"10666449","id":"PMC_10666449","title":"An 'environment to nucleus' signaling system operates in B lymphocytes: redox status modulates BSAP/Pax-5 activation through Ref-1 nuclear translocation.","date":"2000","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/10666449","citation_count":87,"is_preprint":false},{"pmid":"7777508","id":"PMC_7777508","title":"Pax5 (BSAP) regulates the murine immunoglobulin 3' alpha enhancer by suppressing binding of NF-alpha P, a protein that controls heavy chain transcription.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7777508","citation_count":83,"is_preprint":false},{"pmid":"9120274","id":"PMC_9120274","title":"Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9120274","citation_count":83,"is_preprint":false},{"pmid":"12446773","id":"PMC_12446773","title":"Early B-cell factor, E2A, and Pax-5 cooperate to activate the early B cell-specific mb-1 promoter.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12446773","citation_count":82,"is_preprint":false},{"pmid":"14608905","id":"PMC_14608905","title":"The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.","date":"2003","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14608905","citation_count":80,"is_preprint":false},{"pmid":"11342298","id":"PMC_11342298","title":"Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis.","date":"2001","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11342298","citation_count":74,"is_preprint":false},{"pmid":"22127921","id":"PMC_22127921","title":"The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22127921","citation_count":68,"is_preprint":false},{"pmid":"8664547","id":"PMC_8664547","title":"The role of BSAP (Pax-5) in B-cell development.","date":"1995","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/8664547","citation_count":67,"is_preprint":false},{"pmid":"16680144","id":"PMC_16680144","title":"Transcription factor Pax5 (BSAP) transactivates the RAG-mediated V(H)-to-DJ(H) rearrangement of immunoglobulin genes.","date":"2006","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16680144","citation_count":60,"is_preprint":false},{"pmid":"32646889","id":"PMC_32646889","title":"DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch.","date":"2021","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/32646889","citation_count":56,"is_preprint":false},{"pmid":"9092562","id":"PMC_9092562","title":"The Pax-5 gene is alternatively spliced during B-cell development.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9092562","citation_count":56,"is_preprint":false},{"pmid":"8144891","id":"PMC_8144891","title":"The transcription factor BSAP (NF-HB) is essential for immunoglobulin germ-line epsilon transcription.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8144891","citation_count":56,"is_preprint":false},{"pmid":"9618759","id":"PMC_9618759","title":"Loss- and gain-of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation.","date":"1998","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9618759","citation_count":55,"is_preprint":false},{"pmid":"30842609","id":"PMC_30842609","title":"PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30842609","citation_count":55,"is_preprint":false},{"pmid":"10197586","id":"PMC_10197586","title":"The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10197586","citation_count":55,"is_preprint":false},{"pmid":"10455134","id":"PMC_10455134","title":"AML1 (CBFalpha2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10455134","citation_count":54,"is_preprint":false},{"pmid":"8579748","id":"PMC_8579748","title":"BSAP: a key regulator of B-cell development and differentiation.","date":"1995","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/8579748","citation_count":53,"is_preprint":false},{"pmid":"9190940","id":"PMC_9190940","title":"The transcription factor B cell-specific activator protein (BSAP) enhances both IL-4- and CD40-mediated activation of the human epsilon germline promoter.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9190940","citation_count":53,"is_preprint":false},{"pmid":"34301800","id":"PMC_34301800","title":"Pax5 regulates B cell immunity by promoting PI3K signaling via PTEN down-regulation.","date":"2021","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34301800","citation_count":51,"is_preprint":false},{"pmid":"10688639","id":"PMC_10688639","title":"BSAP can repress enhancer activity by targeting PU.1 function.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10688639","citation_count":50,"is_preprint":false},{"pmid":"9442394","id":"PMC_9442394","title":"Essential functions of Pax-5 (BSAP) in pro-B cell development.","date":"1997","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/9442394","citation_count":49,"is_preprint":false},{"pmid":"17717432","id":"PMC_17717432","title":"Diagnostic uses of Pax5 immunohistochemistry.","date":"2007","source":"Advances in anatomic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17717432","citation_count":49,"is_preprint":false},{"pmid":"11044090","id":"PMC_11044090","title":"The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5.","date":"2000","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/11044090","citation_count":49,"is_preprint":false},{"pmid":"9506950","id":"PMC_9506950","title":"Dependence of BSAP repressor and activator functions on BSAP concentration.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9506950","citation_count":47,"is_preprint":false},{"pmid":"17050077","id":"PMC_17050077","title":"Pax-5 expression in nonhematopoietic tissues.","date":"2006","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17050077","citation_count":46,"is_preprint":false},{"pmid":"12560221","id":"PMC_12560221","title":"Pax5 determines B- versus T-cell fate and does not block early myeloid-lineage development.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12560221","citation_count":45,"is_preprint":false},{"pmid":"12453881","id":"PMC_12453881","title":"Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12453881","citation_count":45,"is_preprint":false},{"pmid":"28978690","id":"PMC_28978690","title":"Aryl Hydrocarbon Receptor Activation Suppresses EBF1 and PAX5 and Impairs Human B Lymphopoiesis.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28978690","citation_count":42,"is_preprint":false},{"pmid":"8639790","id":"PMC_8639790","title":"Altered expression of Pax-5 gene in human myeloma cells.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8639790","citation_count":41,"is_preprint":false},{"pmid":"34547766","id":"PMC_34547766","title":"Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34547766","citation_count":40,"is_preprint":false},{"pmid":"14594818","id":"PMC_14594818","title":"CD40 stimulation induces Pax5/BSAP and EBF activation through a APE/Ref-1-dependent redox mechanism.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14594818","citation_count":38,"is_preprint":false},{"pmid":"36387144","id":"PMC_36387144","title":"PAX5 alterations in B-cell acute lymphoblastic leukemia.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36387144","citation_count":37,"is_preprint":false},{"pmid":"10430025","id":"PMC_10430025","title":"Monoallelic expression of Pax5: a paradigm for the haploinsufficiency of mammalian Pax genes?","date":"1999","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10430025","citation_count":37,"is_preprint":false},{"pmid":"12457614","id":"PMC_12457614","title":"Roles of EBF and Pax-5 in B lineage commitment and development.","date":"2002","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12457614","citation_count":37,"is_preprint":false},{"pmid":"10572073","id":"PMC_10572073","title":"BSAP/Pax5A expression blocks survival and expansion of early myeloid cells implicating its involvement in maintaining commitment to the B-lymphocyte lineage.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10572073","citation_count":37,"is_preprint":false},{"pmid":"21765475","id":"PMC_21765475","title":"Dominant-negative mechanism of leukemogenic PAX5 fusions.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21765475","citation_count":36,"is_preprint":false},{"pmid":"17626071","id":"PMC_17626071","title":"Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program.","date":"2007","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/17626071","citation_count":35,"is_preprint":false},{"pmid":"15195108","id":"PMC_15195108","title":"Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray.","date":"2004","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/15195108","citation_count":35,"is_preprint":false},{"pmid":"17717600","id":"PMC_17717600","title":"B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17717600","citation_count":35,"is_preprint":false},{"pmid":"21217775","id":"PMC_21217775","title":"PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21217775","citation_count":35,"is_preprint":false},{"pmid":"9705955","id":"PMC_9705955","title":"Early function of Pax5 (BSAP) before the pre-B cell receptor stage of B lymphopoiesis.","date":"1998","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9705955","citation_count":34,"is_preprint":false},{"pmid":"29713018","id":"PMC_29713018","title":"A PAX5-OCT4-PRDM1 developmental switch specifies human primordial germ cells.","date":"2018","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29713018","citation_count":34,"is_preprint":false},{"pmid":"14500810","id":"PMC_14500810","title":"Requirements for selective recruitment of Ets proteins and activation of mb-1/Ig-alpha gene transcription by Pax-5 (BSAP).","date":"2003","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/14500810","citation_count":34,"is_preprint":false},{"pmid":"8786288","id":"PMC_8786288","title":"B cell lineage-specific activator protein (BSAP). A player at multiple stages of B cell development.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8786288","citation_count":33,"is_preprint":false},{"pmid":"9722295","id":"PMC_9722295","title":"Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma.","date":"1998","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9722295","citation_count":33,"is_preprint":false},{"pmid":"21043826","id":"PMC_21043826","title":"Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.","date":"2010","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21043826","citation_count":33,"is_preprint":false},{"pmid":"33619557","id":"PMC_33619557","title":"EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33619557","citation_count":32,"is_preprint":false},{"pmid":"17682124","id":"PMC_17682124","title":"Human BSAP and BLIMP1 conform an autoregulatory feedback loop.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17682124","citation_count":30,"is_preprint":false},{"pmid":"33613108","id":"PMC_33613108","title":"DGCR5 is activated by PAX5 and promotes pancreatic cancer via targeting miR-3163/TOP2A and activating Wnt/β-catenin pathway.","date":"2021","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33613108","citation_count":30,"is_preprint":false},{"pmid":"15561888","id":"PMC_15561888","title":"Different isoforms of BSAP regulate expression of AID in normal and chronic lymphocytic leukemia B cells.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15561888","citation_count":29,"is_preprint":false},{"pmid":"36064939","id":"PMC_36064939","title":"The MBNL1/circNTRK2/PAX5 pathway regulates aerobic glycolysis in glioblastoma cells by encoding a novel protein NTRK2-243aa.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36064939","citation_count":29,"is_preprint":false},{"pmid":"9743352","id":"PMC_9743352","title":"Overexpression of BSAP/Pax-5 inhibits switching to IgA and enhances switching to IgE in the I.29 mu B cell line.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9743352","citation_count":29,"is_preprint":false},{"pmid":"11841448","id":"PMC_11841448","title":"Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells.","date":"2002","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/11841448","citation_count":28,"is_preprint":false},{"pmid":"30257940","id":"PMC_30257940","title":"PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30257940","citation_count":28,"is_preprint":false},{"pmid":"36516256","id":"PMC_36516256","title":"PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36516256","citation_count":27,"is_preprint":false},{"pmid":"10748034","id":"PMC_10748034","title":"BSAP (Pax5)-importin alpha 1 (Rch1) interaction identifies a nuclear localization sequence.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10748034","citation_count":27,"is_preprint":false},{"pmid":"17431414","id":"PMC_17431414","title":"Rare expression of BSAP (PAX-5) in mature T-cell lymphomas.","date":"2007","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/17431414","citation_count":26,"is_preprint":false},{"pmid":"28076843","id":"PMC_28076843","title":"Pax-5 is a potent regulator of E-cadherin and breast cancer malignant processes.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28076843","citation_count":26,"is_preprint":false},{"pmid":"14676435","id":"PMC_14676435","title":"Pax5 expression in non-Hodgkin's lymphomas and acute leukemias.","date":"2003","source":"Journal of Korean medical science","url":"https://pubmed.ncbi.nlm.nih.gov/14676435","citation_count":26,"is_preprint":false},{"pmid":"10350329","id":"PMC_10350329","title":"Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32).","date":"1999","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/10350329","citation_count":25,"is_preprint":false},{"pmid":"16918686","id":"PMC_16918686","title":"Pax5--a critical inhibitor of plasma cell fate.","date":"2006","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16918686","citation_count":24,"is_preprint":false},{"pmid":"33004416","id":"PMC_33004416","title":"EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.","date":"2020","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/33004416","citation_count":24,"is_preprint":false},{"pmid":"15067064","id":"PMC_15067064","title":"Pax-5 is essential for kappa sterile transcription during Ig kappa chain gene rearrangement.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15067064","citation_count":24,"is_preprint":false},{"pmid":"32780801","id":"PMC_32780801","title":"Repression of the B cell identity factor Pax5 is not required for plasma cell development.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32780801","citation_count":24,"is_preprint":false},{"pmid":"35156727","id":"PMC_35156727","title":"The PAX5-JAK2 translocation acts as dual-hit mutation that promotes aggressive B-cell leukemia via nuclear STAT5 activation.","date":"2022","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/35156727","citation_count":24,"is_preprint":false},{"pmid":"35947077","id":"PMC_35947077","title":"Biallelic PAX5 mutations cause hypogammaglobulinemia, sensorimotor deficits, and autism spectrum disorder.","date":"2022","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35947077","citation_count":24,"is_preprint":false},{"pmid":"36077495","id":"PMC_36077495","title":"The Pleiotropy of PAX5 Gene Products and Function.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36077495","citation_count":23,"is_preprint":false},{"pmid":"12044782","id":"PMC_12044782","title":"DNA methylation dominates transcriptional silencing of Pax5 in terminally differentiated B cell lines.","date":"2002","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12044782","citation_count":23,"is_preprint":false},{"pmid":"30194145","id":"PMC_30194145","title":"Pax-5 Inhibits Breast Cancer Proliferation Through MiR-215 Up-regulation.","date":"2018","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30194145","citation_count":22,"is_preprint":false},{"pmid":"18343782","id":"PMC_18343782","title":"PAX-5 expression in pulmonary neuroendocrine neoplasms: its usefulness in surgical and fine-needle aspiration biopsy specimens.","date":"2008","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18343782","citation_count":22,"is_preprint":false},{"pmid":"10368252","id":"PMC_10368252","title":"The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation.","date":"1999","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/10368252","citation_count":22,"is_preprint":false},{"pmid":"39179932","id":"PMC_39179932","title":"Transcriptional function of E2A, Ebf1, Pax5, Ikaros and Aiolos analyzed by in vivo acute protein degradation in early B cell development.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39179932","citation_count":21,"is_preprint":false},{"pmid":"23163626","id":"PMC_23163626","title":"PAX8 and PAX5 are differentially expressed in B-cell and T-cell lymphomas.","date":"2012","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/23163626","citation_count":21,"is_preprint":false},{"pmid":"25595912","id":"PMC_25595912","title":"LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25595912","citation_count":21,"is_preprint":false},{"pmid":"15967678","id":"PMC_15967678","title":"Deficient B lymphopoiesis in murine senescence: potential roles for dysregulation of E2A, Pax-5, and STAT5.","date":"2005","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15967678","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47051,"output_tokens":11623,"usd":0.157749,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22521,"output_tokens":5883,"usd":0.12984,"stage2_stop_reason":"end_turn"},"total_usd":0.287589,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"PAX5 encodes the transcription factor BSAP; the intact paired domain is both necessary and sufficient for DNA binding of BSAP, and its DNA-binding sequence specificity differs from the related Pax-1 protein.\",\n      \"method\": \"Biochemical purification, cDNA cloning, DNA binding studies (EMSA)\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical purification and cDNA cloning with in vitro binding assays; foundational identification paper\",\n      \"pmids\": [\"1516825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"BSAP (PAX5) directly binds a high-affinity site in the CD19 gene promoter (occupying it in vivo in B cells but not in plasma or HeLa cells) and confers B-cell specificity in reporter assays, establishing CD19 as a direct PAX5 transcriptional target.\",\n      \"method\": \"In vitro protein-DNA binding, in vivo footprinting, transient transfection reporter assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (EMSA, in vivo footprinting, reporter assay); replicated in subsequent gene-targeting studies\",\n      \"pmids\": [\"1375324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Targeted disruption of Pax5 in mice completely blocks B cell development at an early pro-B (pre-BI) cell stage, defining an essential role for Pax5 in early B lymphopoiesis, and also causes abnormal patterning of the posterior midbrain.\",\n      \"method\": \"Germline gene targeting (knockout mouse), histology, flow cytometry\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with defined cellular phenotype; widely replicated foundational study\",\n      \"pmids\": [\"8001127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"BSAP is required for LPS-induced B cell proliferation; antisense-mediated suppression of BSAP reduced proliferation, and overexpression stimulated proliferation, identifying BSAP as a rate-limiting regulator of B cell proliferation.\",\n      \"method\": \"Antisense oligonucleotide knockdown, overexpression by transfection, proliferation assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two methods (antisense KD and OE) in a single lab with defined proliferative phenotype\",\n      \"pmids\": [\"7511679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"BSAP binds the Iε promoter (forming complex 3) and is essential for LPS/IL-4-induced immunoglobulin germ-line epsilon transcription; a BSAP binding site from a heterologous promoter can substitute functionally for the epsilon-associated site.\",\n      \"method\": \"EMSA, transient transfection reporter assays (CAT)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus functional reporter assay, single lab\",\n      \"pmids\": [\"8144891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Three amino acids at positions 42, 44, and 47 of the paired domain N-terminal subdomain determine the difference in DNA-binding specificity between Pax-6 and BSAP (Pax-5); mutating these three Pax-6 residues to the corresponding BSAP residues completely switches binding specificity to BSAP.\",\n      \"method\": \"In vitro mutagenesis of fusion proteins, EMSA, transactivation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct mutagenesis plus in vitro binding reconstitution establishing specific residues responsible for DNA-binding specificity\",\n      \"pmids\": [\"7739566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"BSAP represses the immunoglobulin heavy chain 3' alpha enhancer by blocking binding of NF-αP (an Ets family member) to the adjacent αP element; triple-helix-forming oligonucleotide blocking of BSAP binding in vivo derepressed the αP footprint and increased endogenous IgH transcription.\",\n      \"method\": \"In vitro binding, in vivo footprinting, triple-helix oligonucleotide transfection, reporter assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo footprinting plus functional reporter assay plus oligonucleotide blocking, single lab\",\n      \"pmids\": [\"7777508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The C-terminal serine/threonine/proline-rich region of BSAP contains a 55-amino-acid transactivation domain that is active from promoter and enhancer positions; this domain is negatively regulated by adjacent extreme C-terminal sequences; both elements function as an independent module conserved in Pax-2 and Pax-8.\",\n      \"method\": \"In vitro mutagenesis, transient transfection reporter assays, GAL4 fusion assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with functional reporter assay defining specific domain boundaries; cross-validated in multiple Pax family members\",\n      \"pmids\": [\"8617244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Pax-5 (BSAP) functions as a cell-type-specific docking protein that recruits Ets proto-oncogene family proteins (Ets-1, Net, Elk-1 but not SAP1a) to form functional ternary complexes on the mb-1 promoter; complex assembly requires only the Pax-5 paired box and ETS DNA-binding domains; a single valine in the ETS domain of SAP1a versus aspartic acid in other Ets proteins determines selectivity.\",\n      \"method\": \"EMSA (ternary complex formation), mutagenesis, transient transfection reporter assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of ternary complex plus mutagenesis identifying specific residues; functionally validated in pre-B cell reporter assays\",\n      \"pmids\": [\"8804314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"BSAP directly activates the human epsilon germline promoter through binding sites identified by EMSA, contributing to both IL-4-dependent induction and CD40-mediated up-regulation of epsilon germline transcription in human B cells.\",\n      \"method\": \"EMSA, luciferase reporter assays with site-directed mutation of BSAP binding site\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus functional reporter assay with binding site mutations, single lab\",\n      \"pmids\": [\"9190940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Pax5 is required for VH-to-DHJH rearrangement at the IgH locus in adult pro-B cells (~50-fold reduction) while DH-to-JH rearrangements occur at normal frequency; fetal and adult B lymphopoiesis have differential dependency on Pax5.\",\n      \"method\": \"Pax5 knockout mouse analysis, PCR-based rearrangement assays, transplantation experiments\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with quantitative molecular readout; multiple experimental conditions\",\n      \"pmids\": [\"9042861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Overexpression of BSAP in a late B cell line suppressed Ig synthesis and reduced Blimp-1 expression, inhibiting differentiation to plasma cell phenotype; BSAP overexpression suppressed spontaneous appearance of high-Ig-secreting cells.\",\n      \"method\": \"Stable transfection, overexpression of BSAP expression plasmid, flow cytometry, Ig secretion assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — OE experiment with multiple phenotypic readouts (Blimp-1, syndecan-1, Ig secretion), single lab\",\n      \"pmids\": [\"9120274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Cooperation of Pax2 and Pax5 is essential for normal functioning of the organizing center at the midbrain-hindbrain junction: compound heterozygous Pax5/Pax2 mutant mice show severe midbrain-cerebellar defects, and biallelic loss of both factors deletes the entire posterior midbrain/cerebellum.\",\n      \"method\": \"Double-mutant mouse genetics (Pax5 knockout × Krd deletion of Pax2 locus), morphological analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in compound mutant mice with defined morphological phenotype\",\n      \"pmids\": [\"9159136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Pax5 directly activates Ig-alpha (mb-1), N-myc, and LEF-1 genes and represses PD-1 in pro-B cells, as shown using a hormone-inducible BSAP-estrogen receptor fusion in Pax5-deficient pre-BI cells; the paired domain alone (without transactivation domain) was sufficient to restore mb-1 and LEF-1 expression, suggesting PAX5 acts as a docking protein for other factors at those genes.\",\n      \"method\": \"Hormone-inducible BSAP-ER fusion in Pax5-/- pre-BI cells, loss- and gain-of-function experiments, gene expression analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible reconstitution in null cells with domain-deletion analysis; multiple target genes tested; direct regulation demonstrated\",\n      \"pmids\": [\"9545244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BSAP activator motifs have ~20-fold higher binding affinity than repressor motifs; a concentration-dependent mechanism selectively targets BSAP activities such that at higher concentrations repressor functions are engaged, while at lower concentrations only activator functions are maintained.\",\n      \"method\": \"DNA binding affinity measurements, reporter assays with swapped activator/repressor motifs\",\n      \"journal\": \"Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative binding and functional assays, single lab\",\n      \"pmids\": [\"9506950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Pax5 arrests B lymphopoiesis at a stage that is unresponsive to pre-BCR signaling; pre-BCR is stably expressed on Pax5-/- pre-BI cells but fails to signal; BCL2 overexpression does not rescue the block, indicating Pax5 has a role beyond survival signaling at this stage.\",\n      \"method\": \"Transgenic rescue experiments (Igmu, Igmu-Igbeta, bcl2 transgenes in Pax5-/- mice), in vitro culture assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic rescue attempts in null mice with defined signaling readout; epistasis analysis\",\n      \"pmids\": [\"9705955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The partial homeodomain of Pax5 directly binds TBP (the TATA-binding protein) and the underphosphorylated form of Rb in vivo (by co-immunoprecipitation) and in vitro; interaction with TBP links Pax5 to the basal transcription machinery via TFIID; Rb interaction is cell-cycle regulated.\",\n      \"method\": \"Co-immunoprecipitation, in vitro GST pulldown, mutagenesis mapping\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP plus in vitro pulldown with domain mapping, single lab\",\n      \"pmids\": [\"10197586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"AML1 (CBFα2) physically interacts with the paired DNA-binding domain of BSAP/PAX5, and the two proteins synergistically activate the B-cell-specific blk promoter by more than 50-fold in transient transfection assays.\",\n      \"method\": \"In vitro binding assay, co-immunoprecipitation, transient transfection reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro binding plus co-IP plus functional reporter, single lab\",\n      \"pmids\": [\"10455134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Pax5 exerts transcriptional repression by recruiting Groucho-family corepressors: yeast two-hybrid identified Grg4 as a Pax5 partner; interaction involves the octapeptide motif and C-terminal domain of Pax5, and the Q and SP regions of Grg4; Grg4 efficiently represses Pax5 transcriptional activity in an octapeptide-dependent manner; this Pax/Groucho interaction is conserved in Drosophila.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, domain deletion analysis, transient transfection reporter assays, Drosophila functional assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — yeast two-hybrid discovery + in vivo co-IP + domain mapping + functional reporter + cross-species validation; multiple orthogonal methods\",\n      \"pmids\": [\"10811620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BSAP/Pax5 directly interacts with PU.1 through their respective DNA-binding domains; BSAP represses PU.1 transactivation through the BSAP inhibitory domain (residues 358–385) targeting PU.1 transactivation residues 7–30; this repression can be reversed by the coactivator p300.\",\n      \"method\": \"Co-immunoprecipitation, EMSA, transient transfection reporter assays with domain deletion mutants\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional domain mapping in reporter assays, single lab\",\n      \"pmids\": [\"10688639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Nuclear translocation of Ref-1 (APE1) in response to oxidative stress (H2O2) in B lymphocytes transiently increases its nuclear levels and enhances BSAP/Pax5 DNA-binding activity; Ref-1 co-transfection increases Pax5 activation of the CD19 promoter 5–8-fold.\",\n      \"method\": \"Western blot, in situ immunocytochemistry, EMSA, co-transfection reporter assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cellular fractionation plus EMSA plus co-transfection, single lab with multiple methods\",\n      \"pmids\": [\"10666449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Conditional inactivation of Pax5 in mature B cells (via CD19-cre or Mx-cre) causes loss of B cell identity: downregulation of B cell-specific genes and surface antigens, and upregulation of non-B lymphoid genes, demonstrating Pax5 is continuously required to maintain B cell identity throughout B lymphopoiesis.\",\n      \"method\": \"Conditional knockout mouse (Cre-lox), gene expression analysis, flow cytometry\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic loss-of-function with comprehensive phenotypic characterization; replicated in multiple cre drivers\",\n      \"pmids\": [\"11420047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Pax5 directly represses transcription of Notch1, thereby blocking T cell development; pan-hematopoietic Pax5 expression strongly promoted B cell development at the expense of T lymphopoiesis but did not block myeloid development.\",\n      \"method\": \"Ikaros-locus knockin of Pax5 minigene, conditional/constitutive activation, flow cytometry, gene expression analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain-of-function knockin model with defined mechanistic readout (Notch1 repression); multiple experimental conditions\",\n      \"pmids\": [\"12479824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Pax5 interacts with Daxx via the partial homeodomain of Pax5 and C-terminal fragment of Daxx; this interaction can result in either transcriptional corepression or coactivation in B cells; coactivation involves recruitment of CBP (co-precipitated in complexes containing Pax5, Daxx, and CBP).\",\n      \"method\": \"Yeast two-hybrid, transient transfection reporter assays, co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid + co-IP + functional reporter, single lab\",\n      \"pmids\": [\"11799127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Early B cell factor (EBF), E2A, and Pax-5 cooperate to activate the mb-1 promoter: in vivo footprinting showed occupancy of EBF, E-box, and Pax-5 binding sites; EBF and E2A synergistically activated the promoter in non-B cells, and Pax-5 (with Ets partners) is required at all mb-1-expressing stages.\",\n      \"method\": \"In vivo footprinting, transient transfection reporter assays, DNA microarray expression analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo footprinting plus functional reporter assays plus expression profiling, single lab\",\n      \"pmids\": [\"12446773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD40 stimulation induces nuclear translocation of APE/Ref-1, which then modulates DNA-binding activity of Pax5a/BSAP and EBF in activated B cells; repression of APE/Ref-1 blocks CD40-mediated Pax5a activation; Pax5a physically interacts with EBF and enhances EBF DNA-binding activity.\",\n      \"method\": \"Co-immunoprecipitation, EMSA, nuclear fractionation, transient transfection reporter assay, siRNA knockdown of Ref-1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus EMSA plus functional reporter plus knockdown, single lab\",\n      \"pmids\": [\"14594818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mutations in the β-hairpin/β-turn of the Pax-5 paired domain DNA-binding domain reduce DNA sequence recognition and mb-1 transcription activation; specific amino acids contacting Ets-1 in the crystal structure are required for Ets recruitment and mb-1 transcription; mutation Q22A selectively abolishes Fli-1 recruitment without affecting GABPα recruitment.\",\n      \"method\": \"Crystal structure-guided mutagenesis, cell-based transcription assay, in vitro EMSA\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure-guided mutagenesis with cell-based functional assay; defines specific contact residues for partner selectivity\",\n      \"pmids\": [\"14500810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Pax5 induces large-scale contraction of the IgH locus and distal VH-DJH rearrangements; reconstitution of Pax5 in Pax5-/- pro-B cells is sufficient to trigger locus contraction and distal VH-DJH recombination; ectopic Pax5 in thymocytes induces only proximal VH-DJH rearrangements (no locus contraction), indicating a pro-B-specific cofactor is required.\",\n      \"method\": \"Retroviral Pax5 reconstitution in Pax5-/- pro-B cells, 3D FISH locus contraction assay, VDJ recombination PCR, Ikaros-Pax5 knockin thymocyte analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic reconstitution plus 3D FISH plus recombination PCR; multiple complementary approaches in same study\",\n      \"pmids\": [\"15004008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Pax-5 directly activates kappa sterile transcription and is required for Ig kappa chain gene rearrangement; the transactivation domain of Pax-5 is required for this function; in Pax5-deficient pre-BI cells the Jκ locus localizes to the nuclear periphery (repressive compartment), and Pax5 expression repositions it and enables rearrangement.\",\n      \"method\": \"Hormone-inducible Pax5 reconstitution in Pax5-/- pre-BI cells, RT-PCR, FISH nuclear localization assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible reconstitution in null cells + FISH nuclear localization + domain analysis, multiple orthogonal methods\",\n      \"pmids\": [\"15067064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Pax5 directly binds multiple sites in VH gene coding regions in vitro and occupies VH genes in early B lineage cells in vivo; Pax5 physically interacts with the RAG1-RAG2 complex to enhance RAG-mediated VH recombination signal sequence cleavage and recombination of a VH gene substrate.\",\n      \"method\": \"ChIP, EMSA, co-immunoprecipitation (Pax5–RAG1/RAG2), in vitro V(D)J recombination assay\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP plus in vitro RAG interaction plus in vitro cleavage/recombination assay; multiple orthogonal methods\",\n      \"pmids\": [\"16680144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Deletion of Pax5 in Pax5-deficient DT40 B cells leads to loss of BCR signaling, upregulation of Blimp-1 and XBP-1, downregulation of Bcl-6, and elevated IgM secretion, demonstrating that Pax5 represses plasma cell differentiation; restoration of Pax5 expression normalizes this transcriptional program.\",\n      \"method\": \"Gene targeting (Pax5 deletion in DT40), rescue by Pax5 re-expression, RT-PCR, IgM secretion assay, BCR signaling assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO plus rescue reconstitution with multiple molecular readouts in same study\",\n      \"pmids\": [\"16546097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Pax5 in B lymphomas maintains expression of BCR signaling components (including CD79a/Igα) while repressing ITAM antagonists CD22 and PIR-B; Pax5-dependent BCR/ITAM signaling promotes neoplastic growth, as shown by dominant-negative Pax5 and Pax5 knockdown reducing lymphoma cell expansion.\",\n      \"method\": \"Tamoxifen-inducible Pax5-ER fusion protein, dominant-negative Pax5, shRNA knockdown, expression profiling, Syk inhibitor pharmacology\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible gain-of-function plus DN and KD loss-of-function with expression profiling and defined signaling pathway; multiple orthogonal approaches\",\n      \"pmids\": [\"17717600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BSAP/Pax5 directly binds Wp (Epstein-Barr virus transforming promoter) on the viral genome in transformed B cells (ChIP); mutation of BSAP binding sites in recombinant EBV completely abolishes Wp activity and outgrowth of transformed cells in B cells, while EBV entry into epithelial cells is unaffected.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) on viral genome, recombinant EBV with Wp BSAP binding site mutations\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP plus recombinant virus mutagenesis with biological readout; rigorous mechanistic test\",\n      \"pmids\": [\"17626071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BSAP/PAX5 directly represses PRDM1 (Blimp1) transcription by binding to its promoter in vivo, forming an autoregulatory negative-feedback loop that maintains B cell identity and restrains plasma cell differentiation.\",\n      \"method\": \"EMSA, ChIP, ectopic BSAP expression with PRDM1 promoter reporter (including BSAP binding site mutant)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — EMSA plus ChIP plus functional reporter with site mutation; multiple orthogonal methods\",\n      \"pmids\": [\"17682124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The nuclear localization of BSAP/Pax5 is mediated by a defined NLS sequence (NKRKRDE, amino acids 195–201) in the central domain that binds importin alpha1 (Rch1); this NLS was confirmed by yeast two-hybrid, GST pulldown, and by conferring nuclear localization on GFP fusion proteins.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown, GFP-fusion nuclear localization assay, mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — yeast two-hybrid + in vitro pulldown + live cell localization assay with mutagenesis; multiple orthogonal methods\",\n      \"pmids\": [\"10748034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PAX5 fusion leukemia proteins act as dominant-negatives by multimerizing their DNA-binding domains (via partner-derived oligomerization sequences), resulting in extremely stable chromatin binding (measured by FRAP) and competition with wild-type PAX5 for target sites; tetramerization (not corepressor-binding motifs) is necessary and sufficient for dominant-negative activity.\",\n      \"method\": \"FRAP in living cells, in vitro DNA binding assays, domain deletion/mutagenesis, artificial dimerization/trimerization/tetramerization domain fusions\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — FRAP plus in vitro binding reconstitution plus systematic domain dissection with artificial oligomerization domains; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"21765475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PAX5-PML fusion protein acts as dual dominant-negative for both PAX5 and PML: it inhibits PAX5 transcriptional activity and suppresses PAX5 target gene expression (despite retaining PAX5 DBD, it binds promoters through association with endogenous PAX5 rather than direct DNA binding); it also disrupts PML nuclear bodies, inhibits PML sumoylation, and confers apoptosis resistance reversible by arsenic trioxide.\",\n      \"method\": \"Luciferase reporter assay, ChIP, co-immunoprecipitation, sumoylation assay, PML-NB immunofluorescence, apoptosis assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus ChIP plus functional reporter plus NB disruption assay, single lab\",\n      \"pmids\": [\"21217775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOX11 directly binds the PAX5 locus (identified by ChIP-microarray) and regulates PAX5 expression; SOX11 knockdown downregulates PAX5, induces BLIMP1 expression, and promotes plasmacytic differentiation in MCL cells.\",\n      \"method\": \"ChIP-microarray, siRNA knockdown, gene expression profiling, flow cytometry\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus KD with expression profiling, single lab; PAX5 is here an output rather than the actor\",\n      \"pmids\": [\"23321250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EBV noncoding RNA EBER2 directly interacts with PAX5 protein and is required for PAX5 localization to the terminal repeats of the latent EBV genome; this recruitment is mediated by base-pairing between EBER2 and nascent transcripts from the terminal repeat locus; EBER2 knockdown phenocopies PAX5 depletion in upregulating LMP2A/B and LMP1.\",\n      \"method\": \"CHART (Capture Hybridization Analysis of RNA Targets), co-immunoprecipitation (EBER2–PAX5), EBER2 knockdown, reporter/ChIP assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CHART genomic localization + co-IP of RNA-protein complex + knockdown phenocopy + base-pairing mechanism; multiple orthogonal methods\",\n      \"pmids\": [\"25662012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In human primordial germ cell (hPGC) development, PAX5 forms a core transcriptional network with OCT4 and PRDM1; PAX5 switches OCT4 from its pluripotency partner SOX2 to drive germline specification; PAX5 acts upstream of OCT4 and PRDM1 by epistasis; PAX5 loss-of-function impairs hPGC development.\",\n      \"method\": \"ChIP-seq (OCT4 occupancy in hPGCs vs hESCs), gain- and loss-of-function (genome editing), epistasis analysis, in vitro differentiation and xenograft engraftment\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq plus genome editing gain/loss-of-function plus epistasis; multiple orthogonal methods\",\n      \"pmids\": [\"29713018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The PAX5 p.Pro80Arg mutation impairs B lymphoid development and promotes B-ALL with biallelic PAX5 alteration in vivo, demonstrating a gain-of-leukemogenic function for this specific missense mutation.\",\n      \"method\": \"In vivo mouse model with PAX5 P80R knockin, B cell developmental assays, B-ALL disease induction\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockin mouse model with defined cellular phenotype and disease induction\",\n      \"pmids\": [\"30643249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Pax5 restrains PTEN protein expression at the posttranscriptional level (likely through Pten-targeting microRNAs), thereby promoting PI3K-AKT signaling in mature B cells; Pax5-deficient follicular B cells fail to proliferate upon BCR or TLR stimulation due to increased PTEN and impaired PI3K signaling; additional PTEN loss in Pten,Pax5 double-mutant mice rescues follicular and marginal zone B cell numbers but not germinal center formation.\",\n      \"method\": \"Conditional knockout mouse (Pax5 deletion in peripheral B cells), Pten/Pax5 double-mutant mice, Western blot (PTEN protein), PI3K-AKT signaling assays, B cell stimulation/proliferation assays\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO plus double-mutant epistasis plus molecular signaling readout; multiple orthogonal methods in same study\",\n      \"pmids\": [\"34301800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EBF1 and PAX5 bind opposing regulatory elements in the Myc locus and regulate Myc in an opposing manner: EBF1 activates Myc expression (critical for pro-B cell expansion) while ectopic PAX5 in EBF1-deficient cells inhibits cell cycle and reduces Myc expression; Pax5 inactivation reduces EBF1 requirements for pro-B cell expansion.\",\n      \"method\": \"Chromosome conformation analysis, ATAC-seq, ChIP-seq, CRISPR-Cas9 targeting of EBF1-binding sites, reporter assay, conditional KO mouse\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq + ATAC + CCA + CRISPR perturbation + genetic epistasis; multiple orthogonal methods\",\n      \"pmids\": [\"33619557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PAX5 acts as a key activator of CD58 expression at the CD58 locus through an epigenetically defined enhancer; the PAX5 P80R mutation disrupts this enhancer, reducing CD58 expression and conferring blinatumomab resistance in B-ALL.\",\n      \"method\": \"Genome-wide CRISPR screen, transcription factor screen (1639 TFs), genome editing (P80R mutation), ChIP/ATAC-seq at CD58 locus\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide CRISPR screen + targeted genome editing + ChIP/epigenome at specific locus; multiple orthogonal methods\",\n      \"pmids\": [\"36516256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The PAX5-JAK2 fusion protein functions as a nuclear driver of B-ALL: its DNA-binding function (via PAX5 DBD) and kinase activity (via JAK2 domain) are both required for leukemogenesis; PAX5-JAK2 phosphorylates STAT5 in the nucleus, sustaining high levels of active nuclear pSTAT5 and STAT5 target gene expression.\",\n      \"method\": \"Endogenous locus Pax5-Jak2 knockin mouse, domain-specific mutagenesis (kinase-dead, DNA-binding mutants), phospho-STAT5 Western blot/ChIP, RNA-seq\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — endogenous knockin model plus domain mutagenesis plus nuclear signaling readout; multiple orthogonal methods\",\n      \"pmids\": [\"35156727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Biallelic loss-of-function mutations in PAX5 cause hypogammaglobulinemia (due to early B cell developmental block), defective immune responses, aberrant cerebellar foliation, hypoplasia of the substantia nigra and ventral tegmental area (loss of GABAergic neurons), and ASD-like behavioral deficits; lineage tracing identifies Pax5 as a crucial regulator of cerebellar morphogenesis and midbrain GABAergic neurogenesis.\",\n      \"method\": \"Patient-specific Pax5 knockin mouse, flow cytometry, behavioral testing, histology/lineage tracing, immune response assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — patient-specific mouse model with lineage tracing plus multiple orthogonal phenotypic readouts; identifies new roles in brain development\",\n      \"pmids\": [\"35947077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Acute in vivo degradation of Pax5 protein in pro-B, small pre-B, and immature B cells revealed that Pax5 functions predominantly as a transcriptional activator by inducing open chromatin at target genes; Pax5 directly activates Rag1, Rag2, Dntt, Irf4, and Irf8 (contributing to V(D)J recombination); Pax5, like Ebf1, represses the cohesin-release factor Wapl to mediate prolonged loop extrusion across the Igh locus; Pax5 co-activates Igll1 and Vpreb1 surrogate light-chain genes in pro-B cells.\",\n      \"method\": \"Acute protein degradation (dTAG system) in mice, ATAC-seq, ChIP-seq, RNA-seq across multiple B cell developmental stages\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — acute in vivo protein degradation (avoiding compensation) plus genome-wide chromatin and expression analysis across multiple stages; highly rigorous multi-method study\",\n      \"pmids\": [\"39179932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PAX5 directly regulates c-Met transcription in small-cell lung cancer (SCLC) cells; PAX5 binds the c-Met promoter (shown by luciferase reporter and ChIP); phospho-c-Met and PAX5 co-localize in the nucleus and physically interact; PAX5 knockdown decreases SCLC cell viability, especially with c-Met or topoisomerase inhibitors.\",\n      \"method\": \"Luciferase reporter assay, ChIP, co-immunoprecipitation, immunofluorescence co-localization, siRNA knockdown + drug treatment\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional reporter plus co-IP, single lab; context is non-B cell (SCLC)\",\n      \"pmids\": [\"19139719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Repression of Pax5 by Blimp1 is NOT required for plasma cell development; mice expressing a Pax5 minigene ectopically in plasma cells (IghPax5/+) still efficiently develop plasma cells and secrete antibodies, though IgG secretion is modestly decreased and long-lived plasma cells are reduced in older mice.\",\n      \"method\": \"IghPax5/+ knockin mouse (Pax5 minigene expressed from IgH locus), plasma cell development analysis, antibody secretion assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain-of-function knockin with multiple functional readouts; directly tests and refutes a prevailing model\",\n      \"pmids\": [\"32780801\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PAX5 (BSAP) is a paired-domain transcription factor that functions as the master regulator of B cell identity throughout lymphopoiesis: it binds target gene promoters/enhancers via its N-terminal paired domain (with DNA-binding specificity determined by three key residues), recruits Ets family proteins as ternary complex partners, activates B-lineage genes (CD19, mb-1/Igα, N-myc, LEF-1, Rag1/2, Dntt, Igll1/Vpreb1) and represses non-B-lineage and plasma cell genes (Notch1, PD-1, PRDM1/Blimp1) through distinct mechanisms including corepressor recruitment (Groucho/Grg4 via its octapeptide motif), physical antagonism of PU.1, and interaction with TBP/TFIID and Rb; it induces IgH locus contraction to enable distal VH-DJH recombination by repressing the cohesin-release factor Wapl, directly interacts with the RAG1-RAG2 complex to enhance V(D)J cleavage, and posttranscriptionally down-regulates PTEN to promote PI3K-AKT signaling in mature B cells; its nuclear import requires a defined NLS (aa 195–201) that binds importin α1; in leukemia, PAX5 fusion proteins act as dominant-negatives via DBD multimerization and the PAX5-JAK2 fusion phosphorylates nuclear STAT5, while the PAX5 P80R mutation disrupts a CD58 enhancer to confer immunotherapy resistance.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PAX5 (BSAP) is a paired-domain transcription factor that serves as the master regulator of B-cell identity throughout lymphopoiesis, where it is both required to commit progenitors to the B lineage and continuously required to maintain that identity in mature B cells [#2, #21]. Its N-terminal paired domain is necessary and sufficient for sequence-specific DNA binding, with three residues at positions 42, 44 and 47 determining its target specificity relative to other Pax proteins [#0, #5]. PAX5 functions both as a direct activator of B-lineage genes — CD19, mb-1/Igα, N-myc, LEF-1, and the surrogate light-chain genes Igll1/Vpreb1 — and as a repressor of lineage-inappropriate and plasma-cell programs, repressing Notch1 to block T-cell development and repressing PRDM1/Blimp1 in an autoregulatory loop that restrains plasma-cell differentiation [#1, #13, #22, #33, #46]. Acute in vivo degradation establishes that PAX5 acts predominantly as a transcriptional activator that induces open chromatin at target genes, directly activating Rag1, Rag2, Dntt, Irf4 and Irf8 [#46]. Mechanistically, PAX5 operates as a cell-type-specific docking platform: it recruits Ets-family proteins (Ets-1, Net, Elk-1, Fli-1) into ternary complexes on the mb-1 promoter, cooperates with EBF, E2A and AML1, recruits Groucho/Grg4 corepressors through its octapeptide motif, and contacts the basal machinery via TBP and Rb [#8, #16, #17, #18, #24, #26]. It orchestrates antigen-receptor assembly by inducing large-scale IgH locus contraction to enable distal VH-DJH recombination — repressing the cohesin-release factor Wapl to sustain loop extrusion — and by directly interacting with the RAG1-RAG2 complex to enhance V(D)J cleavage [#27, #29, #46]. In mature B cells PAX5 sustains BCR signaling and posttranscriptionally restrains PTEN to promote PI3K-AKT signaling [#31, #41]. PAX5 also functions outside the B lineage, forming a core network with OCT4 and PRDM1 to drive human primordial germ-cell specification [#39]. In leukemia, PAX5 fusion proteins act as dominant-negatives via DNA-binding-domain multimerization, the PAX5-JAK2 fusion drives B-ALL by phosphorylating nuclear STAT5, and the PAX5 P80R mutation disrupts a CD58 enhancer to confer blinatumomab resistance [#35, #43, #44]. Biallelic loss-of-function PAX5 mutations cause human hypogammaglobulinemia with cerebellar and midbrain neurodevelopmental defects [#45].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Establishing the molecular identity of BSAP answered whether a single factor underlies B-cell-specific gene regulation, defining PAX5 as a paired-domain transcription factor with intrinsic DNA-binding specificity and a bona fide B-lineage target.\",\n      \"evidence\": \"Biochemical purification, cDNA cloning and EMSA; in vivo footprinting and reporter assays on the CD19 promoter\",\n      \"pmids\": [\"1516825\", \"1375324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the full target gene network\", \"No structural basis for specificity yet\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Germline knockout answered where PAX5 acts in development, showing it is essential for progression past the early pro-B stage and also patterns the posterior midbrain, revealing a non-redundant role at a developmental checkpoint.\",\n      \"evidence\": \"Pax5 knockout mouse with histology and flow cytometry; antisense knockdown and overexpression proliferation assays\",\n      \"pmids\": [\"8001127\", \"7511679\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the direct target genes mediating the block\", \"Mechanism of midbrain patterning unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Domain dissection answered how DNA-binding specificity is encoded, identifying three paired-domain residues that switch specificity and showing PAX5 can repress by competing for overlapping Ets sites.\",\n      \"evidence\": \"In vitro mutagenesis of paired-domain fusion proteins, EMSA, transactivation assays; in vivo footprinting with triple-helix blocking at the IgH 3' enhancer\",\n      \"pmids\": [\"7739566\", \"7777508\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Repression of the 3' enhancer is Medium-confidence single-lab\", \"No structural model of the paired domain-DNA complex\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identifying the transactivation domain and the Ets-docking function answered how PAX5 actively regulates transcription, defining it as a modular activator and a recruitment platform for partner factors.\",\n      \"evidence\": \"GAL4-fusion and reporter mutagenesis mapping the C-terminal transactivation domain; EMSA ternary-complex reconstitution with Ets proteins and selectivity mutagenesis on the mb-1 promoter\",\n      \"pmids\": [\"8617244\", \"8804314\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous coactivators recruited by the transactivation domain not defined\", \"Ternary complexes shown in vitro/reporter, not at native chromatin\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Inducible reconstitution in null cells answered which genes PAX5 directly controls, distinguishing genes activated via docking from those requiring the transactivation domain, and revealing a concentration-dependent activator/repressor switch.\",\n      \"evidence\": \"Hormone-inducible BSAP-ER in Pax5-/- pre-BI cells with domain deletions; quantitative binding-affinity and motif-swap reporter assays; transgenic rescue of the pre-BCR signaling block\",\n      \"pmids\": [\"9545244\", \"9506950\", \"9705955\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Affinity-threshold model is Medium-confidence single-lab\", \"Identity of docked factors at mb-1/LEF-1 not established\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Partner and corepressor mapping answered how PAX5 mechanistically represses and how it enters the nucleus, identifying Groucho/Grg4 recruitment via the octapeptide, antagonism of PU.1, and a defined importin-α1-binding NLS.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP and domain mapping for Grg4 and PU.1; GST pulldown and GFP-fusion localization assays for the NLS (aa 195-201)\",\n      \"pmids\": [\"10811620\", \"10688639\", \"10748034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PU.1 antagonism is Medium-confidence single-lab\", \"Full corepressor complex composition not defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Conditional inactivation answered whether PAX5 is needed only for commitment or continuously, showing mature B cells lose B identity and dedifferentiate without it, establishing PAX5 as a maintenance factor.\",\n      \"evidence\": \"Cre-lox conditional knockout with expression profiling and flow cytometry\",\n      \"pmids\": [\"11420047\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which targets are most critical for identity maintenance\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Gain-of-function and partner studies answered how PAX5 enforces lineage choice, showing it represses Notch1 to suppress T-cell fate and engages Daxx/CBP for context-dependent regulation.\",\n      \"evidence\": \"Ikaros-locus Pax5 knockin with flow cytometry and expression analysis; yeast two-hybrid and co-IP for Daxx\",\n      \"pmids\": [\"12479824\", \"11799127\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Daxx coactivation/corepression switch is Medium-confidence single-lab\", \"Notch1 repression mechanism at the locus not detailed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Locus-architecture studies answered how PAX5 enables distal antigen-receptor recombination, showing it induces IgH locus contraction and repositions the Igκ locus out of repressive nuclear compartments.\",\n      \"evidence\": \"Retroviral reconstitution in Pax5-/- pro-B cells with 3D FISH and VDJ recombination PCR; FISH nuclear localization of the Jκ locus\",\n      \"pmids\": [\"15004008\", \"15067064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The pro-B-specific cofactor required for contraction was not identified\", \"Molecular link between PAX5 and the contraction machinery unresolved at the time\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Biochemical and genetic studies answered how PAX5 acts directly within V(D)J recombination and how it restrains plasma-cell fate, showing it binds VH coding regions and the RAG1-RAG2 complex to enhance cleavage and represses the Blimp-1/XBP-1 program.\",\n      \"evidence\": \"ChIP, EMSA, RAG1/2 co-IP and in vitro V(D)J recombination assay; Pax5 deletion and rescue in DT40 cells\",\n      \"pmids\": [\"16680144\", \"16546097\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the PAX5-RAG complex not defined\", \"How PAX5 mechanistically enhances cleavage at the active site unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Studies in lymphoma and EBV answered how PAX5 sustains malignant and viral B-cell programs, showing it maintains BCR/ITAM signaling for neoplastic growth, autoregulates PRDM1, and drives the EBV Wp transforming promoter.\",\n      \"evidence\": \"Inducible PAX5-ER, dominant-negative and shRNA approaches with expression profiling; ChIP and recombinant-EBV mutagenesis; EMSA/ChIP/reporter on PRDM1\",\n      \"pmids\": [\"17717600\", \"17682124\", \"17626071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect maintenance of individual BCR components not fully parsed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Work in primordial germ cells answered whether PAX5 functions beyond the B lineage, showing it forms a core network with OCT4 and PRDM1 and switches OCT4 from a pluripotency to a germline program.\",\n      \"evidence\": \"ChIP-seq of OCT4 occupancy, genome-editing gain/loss-of-function, epistasis and xenograft engraftment in human PGCs\",\n      \"pmids\": [\"29713018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PAX5 redirects OCT4 partner choice mechanistically not defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mechanistic dissection of leukemic fusions answered how PAX5 rearrangements drive disease, showing fusion-driven oligomerization of the DNA-binding domain produces dominant-negative, chromatin-locked competitors of wild-type PAX5.\",\n      \"evidence\": \"FRAP in living cells, in vitro DNA binding, and artificial oligomerization-domain fusions; PAX5-PML co-IP, ChIP and PML-NB disruption assays\",\n      \"pmids\": [\"21765475\", \"21217775\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PAX5-PML dual mechanism is Medium-confidence single-lab\", \"Target genes most relevant to transformation not enumerated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Conditional and double-mutant studies answered how PAX5 supports mature-B-cell signaling, showing it posttranscriptionally restrains PTEN to enable PI3K-AKT signaling and opposes EBF1 at the Myc locus.\",\n      \"evidence\": \"Pax5 and Pten/Pax5 conditional and double-mutant mice with PI3K-AKT signaling and proliferation assays; ChIP-seq, ATAC-seq, CCA and CRISPR editing at the Myc locus\",\n      \"pmids\": [\"34301800\", \"33619557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The specific PTEN-targeting microRNAs were not definitively identified\", \"Mechanism of opposing EBF1/PAX5 occupancy at Myc not fully resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"In vivo models of specific mutations answered how PAX5 alterations cause B-ALL and treatment resistance, showing the JAK2 fusion phosphorylates nuclear STAT5 and the P80R mutation disrupts a CD58 enhancer to confer blinatumomab resistance.\",\n      \"evidence\": \"Endogenous-locus Pax5-Jak2 knockin with domain mutagenesis and pSTAT5 readouts; genome-wide CRISPR and TF screens with P80R genome editing and ChIP/ATAC at CD58; P80R knockin disease model; refutation of Blimp1-mediated Pax5 repression requirement\",\n      \"pmids\": [\"35156727\", \"36516256\", \"30643249\", \"32780801\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of nuclear pSTAT5 targets driving leukemogenesis not catalogued\", \"How P80R remodels enhancer chromatin mechanistically not fully resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Acute protein degradation answered the long-standing question of PAX5's predominant regulatory mode without compensation, showing it acts mainly as an activator that opens chromatin at direct targets including Rag1/2, Dntt, Irf4/8 and surrogate light-chain genes, and represses Wapl to sustain Igh loop extrusion.\",\n      \"evidence\": \"dTAG acute degradation in mice with stage-resolved ATAC-seq, ChIP-seq and RNA-seq\",\n      \"pmids\": [\"39179932\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct coactivators delivering chromatin opening not identified\", \"Mechanism of Wapl repression at the molecular level not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PAX5 mechanistically couples to chromatin-remodeling and loop-extrusion machinery to open target genes and reposition antigen-receptor loci remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No defined PAX5-recruited remodeling complex\", \"Direct link between PAX5 and cohesin/Wapl regulation undefined\", \"Structural basis of PAX5-RAG and PAX5-Ets complexes on native chromatin lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 13, 22, 33, 46]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 5, 1, 29]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [8, 13, 24]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [38]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [34, 1]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [44, 47]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 13, 33, 46]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 21, 27, 29]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 12, 39, 45]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [35, 40, 43, 44]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [31, 41, 44]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ETS1\", \"EBF1\", \"RUNX1\", \"TBP\", \"RB1\", \"TLE4\", \"SPI1\", \"RAG1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":10,"faith_total":10,"faith_pct":100.0}}